180 Life Sciences Corp. has filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated August 9, 2023. The supplement includes information from Current Reports filed on various dates from December 4, 2023, to February 16, 2024, and discloses the extension and repricing of certain common stock purchase warrants. The company's common stock is traded on Nasdaq under the symbol 'ATNF'. The last reported sale price of the common stock on Nasdaq was $0.21 per share as of February 15, 2024. The prospectus supplement details the issuance and sale of 666,925 shares of common stock, pre-funded warrants to purchase 3,948,460 shares, and common warrants to purchase 4,615,385 shares. The company was previously notified by Nasdaq of non-compliance with shareholder approval requirements, which has since been rectified...Show More

180 Life Sciences Corp. has filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated August 9, 2023. The supplement includes information from Current Reports filed on various dates from December 4, 2023, to February 16, 2024, and discloses the extension and repricing of certain common stock purchase warrants. The company's common stock is traded on Nasdaq under the symbol 'ATNF'. The last reported sale price of the common stock on Nasdaq was $0.21 per share as of February 15, 2024. The prospectus supplement details the issuance and sale of 666,925 shares of common stock, pre-funded warrants to purchase 3,948,460 shares, and common warrants to purchase 4,615,385 shares. The company was previously notified by Nasdaq of non-compliance with shareholder approval requirements, which has since been rectified with the closing of transactions on December 1, 2023. The stockholder meeting held on February 16, 2024, provided the necessary stockholder approval, allowing the common warrants and existing common warrants to expire on February 16, 2029. Additionally, the company has engaged in cost-cutting initiatives, including salary reductions for key executives, with the potential for accrued amounts to be paid upon future fundraising or forgiven by March 15, 2025.